Swiss drug maker Novartis has agreed to acquire U.S.-based AveXis for $8.7 billion in cash. AveXis is developing a gene-therapy to treat an inherited disease to treat the leading cause of gene-related…
Paul Ausick Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Advanced Accelerator Applications shares made a run early on Monday after it came public that Novartis plans to buy the company.
Chris Lange Here are 13 featured spin-offs already underway and potential spin-offs that could be seen in 2017 and into 2018 that could radically change how Wall Street and Main Street evaluate companies ahead.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
Conatus Pharmaceuticals saw its shares make a handy gain on Friday after the firm announced an exclusive license agreement with Novartis.
Chris Lange The top analyst upgrades, downgrades and other research calls from Wednesday include BHP Billiton, Capital One, Chemours, Constellation Brands, Novartis, Teradyne and Weyerhaeuser.
The top analyst upgrades, downgrades and initiations seen on Wednesday include Chevron, Novartis, Randgold Resources, Urban Outfitters and Vodafone.
The UBS Dividend Ruler portfolio continues to outperform the overall market on a long-term basis, and we continue to think that the outperformance will stay in place for the rest of this…
Conatus Pharmaceuticals saw its shares more than double early on Tuesday after the company reported an exclusive collaboration and license agreement for its cirrhosis treatment.
Chris Lange December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by about 3 to…
November 22, 2016: Here are four stocks trading with relatively heavy volume among 38 equities making new 52-week lows in Tuesday’s session. On the NYSE, advancers led decliners by about 2.5 to…
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
